Going forward, where do you see the
biggest changes and challenges in
cancer diagnostics and therapy?
KP: Counterintuitively, I think we’ll see more
progress in the worst types of tumors, like
glioblastoma and pancreatic cancers. These
are where I think we have the highest chance
of doing trials, and of attracting companies,
and of finding a smoother path through the
regulatory agencies. You have to go after
diseases that currently are not treated well.
And I think for glioblastoma there is a lot of
interest now in combining multiple receptor
tyrosine kinase inhibitors, combining transforming